Holen Sie sich die Stockscreener-App
1.40
6.87%
0.09
Handel nachbörslich:
1.42
0.02
+1.43%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt HRTX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$1.31
Offen:
$1.47
24-Stunden-Volumen:
4.09M
Relative Volume:
2.58
Marktkapitalisierung:
$213.59M
Einnahmen:
$137.74M
Nettoeinkommen (Verlust:
$-27.97M
KGV:
-8.75
EPS:
-0.16
Netto-Cashflow:
$-9.61M
1W Leistung:
-22.65%
1M Leistung:
-35.78%
6M Leistung:
-15.15%
1J Leistung:
-31.37%
1-Tages-Spanne:
$1.315
$1.47
1-Wochen-Bereich:
$1.19
$1.86
52-Wochen-Spanne:
$1.04
$2.68
Heron Therapeutics Inc Stock (HRTX) Company Profile
Firmenname
Heron Therapeutics Inc
Sektor
Branche
Telefon
(858) 251-4400
Adresse
4242 CAMPUS POINT COURT, SUITE 200, SAN DIEGO, CA
Vergleichen Sie HRTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HRTX
Heron Therapeutics Inc
|
1.40 | 195.28M | 137.74M | -27.97M | -9.61M | -0.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Heron Therapeutics Inc Stock (HRTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-09 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-06-13 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-04-23 | Eingeleitet | CapitalOne | Overweight |
| 2024-03-13 | Bestätigt | Needham | Buy |
| 2020-05-27 | Eingeleitet | Guggenheim | Buy |
| 2020-02-20 | Bestätigt | Needham | Buy |
| 2019-01-16 | Bestätigt | Needham | Buy |
| 2018-04-05 | Eingeleitet | Evercore ISI | Outperform |
| 2018-03-19 | Bestätigt | Mizuho | Buy |
| 2018-03-01 | Bestätigt | Needham | Buy |
| 2018-01-03 | Eingeleitet | Leerink Partners | Outperform |
| 2017-09-27 | Eingeleitet | Northland Capital | Outperform |
| 2017-02-27 | Eingeleitet | Needham | Buy |
| 2016-10-26 | Eingeleitet | Aegis Capital | Buy |
| 2016-09-06 | Fortgesetzt | Lake Street | Buy |
| 2016-05-03 | Eingeleitet | Cantor Fitzgerald | Buy |
| 2015-12-10 | Eingeleitet | Lake Street | Buy |
| 2015-09-23 | Bestätigt | Leerink Partners | Outperform |
| 2015-09-02 | Eingeleitet | BofA/Merrill | Buy |
| 2015-08-03 | Bestätigt | Brean Capital | Buy |
| 2015-06-30 | Bestätigt | JMP Securities | Mkt Outperform |
| 2015-06-19 | Bestätigt | Leerink Partners | Outperform |
| 2014-08-07 | Eingeleitet | Noble Financial | Buy |
Alle ansehen
Heron Therapeutics Inc Aktie (HRTX) Neueste Nachrichten
Heron Therapeutics (NASDAQ:HRTX) Lowered to Hold Rating by Wall Street Zen - MarketBeat
Rubric Capital and Director Morgan Make Significant Investments in Heron Therapeutics - AInvest
Heron Therapeutics’ Earnings Call Highlights Growth and Strategy - TipRanks
Rubric capital buys Heron Therapeutics (HRTX) shares worth $3.5m - Investing.com
Heron Therapeutics enters board agreement and completes refinancing transactions By Investing.com - Investing.com Nigeria
Heron Therapeutics: Insider Confidence and Strategic Entry Points in a Volatile Market - AInvest
Heron Therapeutics Strengthens Financial Position with Refinancing - TipRanks
Heron Therapeutics enters board agreement and completes refinancing transactions - Investing.com
Heron Therapeutics Signs Agreement with Patheon - TipRanks
Heron Therapeutics enters supply agreement with Patheon and Thermo Fisher - Investing.com
Heron Therapeutics (NASDAQ:HRTX) Price Target Lowered to $3.00 at Needham & Company LLC - MarketBeat
Heron Therapeutics Convertible Notes - Leerink Partners
Heron Therapeutics Senior Credit Facility - Leerink Partners
Heron Therapeutics Q2 2025 Earnings Call Transcript Released - AInvest
Heron Therapeutics, Inc. (NASDAQ:HRTX) Q2 2025 Earnings Call Transcript - Insider Monkey
Heron Therapeutics (NASDAQ:HRTX) Releases Quarterly Earnings Results, Misses Expectations By $0.01 EPS - MarketBeat
Heron Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Heron Therapeutics Q2 2025 Earnings Call Transcript - MarketBeat
Jefferies Financial Group Inc. Buys Shares of 322,600 Heron Therapeutics, Inc. (NASDAQ:HRTX) - MarketBeat
Heron Therapeutics (HRTX) Reports Q2 Loss, Misses Revenue Estimates - MSN
Heron Therapeutics Announces Strategic Financial Initiatives - The Globe and Mail
Heron Therapeutics 2025 Q2 Earnings Record Net Income and Revenue Growth - AInvest
Heron Therapeutics' Q2 Earnings Miss: A Misunderstood Catalyst for Long-Term Growth? - AInvest
Heron Therapeutics' Q2 2025 Earnings: Strategic Momentum Outpaces Short-Term Setbacks - AInvest
Heron Therapeutics Inc (HRTX) Q2 2025 Earnings Call Highlights: Strong Revenue Growth Amid ... By GuruFocus - Investing.com Canada
TD Asset Management Inc Acquires New Holdings in Heron Therapeutics, Inc. (NASDAQ:HRTX) - MarketBeat
Heron Therapeutics Reports Strong Q2 2025 Results - TipRanks
Heron Therapeutics Raises EBITDA Guidance to $9M-$13M for 2025 Amid Restructuring and ZYNRELEF J-code Milestone - AInvest
Heron Therapeutics HRTX Q2 2025 Earnings Preview Upside Potential Amid Product Expansion - AInvest
Heron Therapeutics Reschedules Second Quarter 2025 Earnings Release and Conference Call to Friday, August 8, 2025 - The Malaysian Reserve
Heron Therapeutics' Q2 2025 Performance and Strategic Realignments: A Blueprint for Long-Term Growth - AInvest
Heron Therapeutics, Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:HRTX) - Seeking Alpha
Heron Therapeutics raises adjusted EBITDA guidance to $9M-$13M for 2025 amid commercial restructuring and ZYNRELEF J-code milestone - MSN
Heron Therapeutics Plummets 28%: What's Fueling the Sudden Sell-Off? - AInvest
Transcript : Heron Therapeutics, Inc., Q2 2025 Earnings Call, Aug 08, 2025 - MarketScreener
Heron Therapeutics Trims Debt And Lifts Yearly Outlook - Finimize
Earnings call transcript: Heron Therapeutics faces Q2 2025 earnings miss, stock drops - Investing.com Canada
Heron Therapeutics Tightens Its Belt And Lifts Its Outlook - Finimize
Heron Therapeutics Q2 2025 slides: Revenue grows, guidance raised despite stock plunge - Investing.com Canada
Heron Therapeutics Inc expected to post a loss of 1 cent a shareEarnings Preview - TradingView
Heron Craters on Q2 Figures - Baystreet.ca
Heron Therapeutics (HRTX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Heron Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 - MarketScreener
Heron Therapeutics: Q2 Earnings Snapshot - San Antonio Express-News
Heron Therapeutics Announces Q2 2025 Financial Results and Highlights Commercial Progress - The Malaysian Reserve
Heron Therapeutics Completes Capital Restructuring - MarketScreener
Heron Therapeutics Q2 revenue rises 3.3%, raises EBITDA guidance - MarketScreener
HERON THERAPEUTICS, INC. /DE/ SEC 10-Q Report - TradingView
Heron Therapeutics completes capital restructuring to reduce debt - Investing.com
Heron Therapeutics announces Q2 2025 financial results and highlights commercial progress - MarketScreener
Heron Therapeutics Announces Q2 2025 Financial Results And Highlights Commercial Progress - TradingView
Finanzdaten der Heron Therapeutics Inc-Aktie (HRTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):